IQVIA Holdings Inc. (IQV)
- Previous Close
228.09 - Open
230.36 - Bid 93.28 x 800
- Ask 269.90 x 900
- Day's Range
228.00 - 232.98 - 52 Week Range
167.42 - 261.73 - Volume
726,885 - Avg. Volume
946,188 - Market Cap (intraday)
42.107B - Beta (5Y Monthly) 1.52
- PE Ratio (TTM)
31.73 - EPS (TTM)
7.29 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
275.82
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
www.iqvia.com87,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: IQV
Performance Overview: IQV
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IQV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IQV
Valuation Measures
Market Cap
42.11B
Enterprise Value
54.51B
Trailing P/E
31.73
Forward P/E
21.05
PEG Ratio (5yr expected)
1.32
Price/Sales (ttm)
2.88
Price/Book (mrq)
6.89
Enterprise Value/Revenue
3.64
Enterprise Value/EBITDA
16.74
Financial Highlights
Profitability and Income Statement
Profit Margin
9.06%
Return on Assets (ttm)
4.98%
Return on Equity (ttm)
22.87%
Revenue (ttm)
14.98B
Net Income Avi to Common (ttm)
1.36B
Diluted EPS (ttm)
7.29
Balance Sheet and Cash Flow
Total Cash (mrq)
1.5B
Total Debt/Equity (mrq)
233.67%
Levered Free Cash Flow (ttm)
1.35B
Research Analysis: IQV
Company Insights: IQV
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: IQV
Weekly Stock List
We see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
Analyst Report: IQVIA Holdings Inc
IQVIA Holdings is the world's largest provider of biopharmaceutical development services and commercial outsourcing services. The company is the result of the 2016 merger of Quintiles Transnational, a contract research organization, and IMS Health, a healthcare data and analytics provider. IQVIA is headquartered in Research Triangle Park, North Carolina. IQVIA provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. IQVIA provides intelligent connections across all aspects of healthcare through its analytics, technology, big data resources and extensive domain expertise. IQVIA's Connected Intelligence delivers actionable insights to enable customers to accelerate the clinical development and commercialization of new therapies. The company has about 86,000 employees. IQVIA has one of the largest collections of healthcare information in the world, which includes more than 1.2 billion comprehensive, longitudinal, non-identified patient records spanning sales and prescription data, medical claims, electronic medical records, genomics and social media.
RatingPrice TargetMarket Digest: AMGN, IQV
Almost two months in 2024, and stocks have seen more recovery highs and the major indices have seen more all-time highs. The S&P 500 (SPX) rose 1.7% in the week ended February 23, the S&P 100 popped 1.9%, the Nasdaq and the Nasdaq 100 added 1.4%, the S&P 400 tacked on 1%, and the Russell 2000 lost 0.9%. For the SPX, the '100,' and both Nasdaq indices, the week was the fifteenth of 17 on the upside; it is 14 of 17 for the '400.' During the 17 weeks, the SPX has gained 23.6%, while both Nasdaq indices are up over 26%. Those are great returns for a full year!
Analyst Report: IQVIA Holdings Inc.
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
RatingPrice Target